Related Experiment Videos
Poor response to all-trans retinoic acid therapy in a t(11;17) PLZF/RAR alpha patient
1Laboratoire de Biologie Cellulaire Hématopoïétique, Institut d'Hématologie, Hôpital Saint Louis, Paris, France.
Abstract:
All-trans retinoic acid (ATRA) is a potent inducer of differentiation and cell death in malignant cells. Its effect is known to be mediated through binding to specific nuclear (RARs and RXRs) or cytoplasmic (CRABP) proteins. ATRA is strikingly effective in acute promyelocytic leukemia (the AML3 subtype) inducing a high incidence of complete remissions. Paradoxically, most AML3 cells harbor an abnormal retinoic acid receptor (PML/RAR alpha) resulting from the t(15;17) translocation. Though few AML3 patients do not respond to ATRA therapy, individualization of these cases is of practical importance. Recently the RAR alpha gene has been demonstrated to be involved in a novel fusion transcript (PLZF/RAR alpha) through a t(11;17) translocation. We describe here the second case of such a patient with a t(11;17)-PLZF/RAR alpha leukemic clone. Southern analysis revealed that the breakpoint in the RAR alpha gene was within the second intron (as for PML/RAR alpha) and the intron separating the second and third zinc finger of the PLZF gene. In vitro, the leukemic cells did not show increased NBT reduction or loss of self-renewal after incubation with ATRA. After therapy with ATRA, only partial remission was obtained. These results suggest that the t(11;17) (PLZF/RAR alpha) case of this study was less responsive to ATRA therapy than t(15;17) (PML/RAR alpha) cases and raises the question of the definition of this novel AML subtype.
Insights
All-trans retinoic acid (ATRA) effectively treats acute promyelocytic leukemia (APL) by inducing cell differentiation. However, a rare PLZF/RAR alpha fusion transcript, unlike PML/RAR alpha, shows reduced ATRA responsiveness in APL patients.
Area of Science:
- Hematology
- Molecular Biology
- Oncology
Background:
- All-trans retinoic acid (ATRA) is a key therapeutic agent for acute promyelocytic leukemia (APL), specifically the AML3 subtype.
- ATRA functions by inducing differentiation and apoptosis in malignant cells, mediated by nuclear retinoic acid receptors (RARs) and related proteins.
- Most APL cases involve the PML/RAR alpha fusion protein resulting from a t(15;17) translocation, which is highly responsive to ATRA.
Observation:
- A novel fusion transcript, PLZF/RAR alpha, arising from a t(11;17) translocation, has been identified in APL.
- This report details the second identified patient with a PLZF/RAR alpha leukemic clone.
- The patient's leukemic cells exhibited no increased NBT reduction or loss of self-renewal in vitro upon ATRA exposure.
Findings:
- Southern analysis confirmed the breakpoint in the RAR alpha gene within the second intron, similar to PML/RAR alpha.
- The breakpoint in the PLZF gene was located in the intron between the second and third zinc finger domains.
- The patient achieved only a partial remission after ATRA therapy, indicating significantly lower responsiveness compared to t(15;17) APL cases.
Implications:
- The findings suggest that APL cases with the PLZF/RAR alpha fusion transcript are less sensitive to ATRA treatment than those with PML/RAR alpha.
- This reduced responsiveness raises questions about the classification and treatment strategies for this distinct subtype of APL.
- Further research is warranted to understand the molecular mechanisms underlying ATRA resistance in PLZF/RAR alpha positive APL and to explore alternative therapeutic approaches.